Cultivar Capital Inc. Invests $814,000 in Johnson & Johnson (NYSE:JNJ)

Cultivar Capital Inc. purchased a new stake in Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 5,192 shares of the company’s stock, valued at approximately $814,000. Johnson & Johnson comprises approximately 0.7% of Cultivar Capital Inc.’s portfolio, making the stock its 12th largest holding.

A number of other large investors have also recently made changes to their positions in JNJ. Trust Co of the South purchased a new position in shares of Johnson & Johnson during the fourth quarter worth about $1,817,000. Sherrill & Hutchins Financial Advisory Inc acquired a new position in Johnson & Johnson during the fourth quarter worth $339,000. Vision Capital Management Inc. raised its position in Johnson & Johnson by 0.6% in the fourth quarter. Vision Capital Management Inc. now owns 50,965 shares of the company’s stock worth $7,988,000 after acquiring an additional 294 shares in the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at $1,458,000. Finally, Twin Peaks Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $202,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Raymond James boosted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price target for the stock from $167.00 to $180.00 in a research note on Friday, December 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Finally, Morgan Stanley dropped their price target on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $177.31.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Up 0.1 %

NYSE:JNJ opened at $158.17 on Friday. Johnson & Johnson has a one year low of $144.95 and a one year high of $175.97. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The company has a market capitalization of $381.15 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 2.62 and a beta of 0.53. The stock has a 50-day simple moving average of $158.71 and a 200 day simple moving average of $156.69.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. Johnson & Johnson’s quarterly revenue was down 9.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.35 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were issued a $1.19 dividend. The ex-dividend date was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.01%. Johnson & Johnson’s payout ratio is currently 34.47%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.